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1. Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice with a
strong impact on public health. The prevalence in the general population is 0.4% and their
incidence increases markedly with age to reach 4-5% in patients over 65 years and 9% in
patients older than 80 years [1]. The main complication associated with this disease is the
development of an embolic event, peripheral or cerebral, strokes being caused by the AF
the most serious and worse prognosis. The risk that a patient suffers a stroke with AF is
related to the presence of other cardioembolic risk factors: hypertension, diabetes mellitus,
heart failure or left ventricular systolic dysfunction, moderately severe, age over 75 years,
female, vascular disease or stroke have shown a previous cerebral (transient or establish‐
ed). These risk factors are reflected in the scales CHADS2 or CHA2DS2-VASC used today to
evaluate this type of patient.
In the management of patients with AF, the most important to improve prognosis is correct
indication of anticoagulant therapy. For over 60 years using vitamin K antagonists (VKAs),
especially warfarin and acenocoumarol, have been shown in several studies a reduction of
70% risk of stroke in AF patients correctly anticoagulated compared with only 22% reduc‐
tion of antiplatelet drugs, or a nonsignificant 19% reduction with acetylsalicylic acid. Thus,
oral anticoagulants (OACs) are recommended in AF patients at moderate-high risk for sroke
and tromboembolism [2]. The VKAs are drugs with proven efficacy, specific antidote in case
of bleeding, possibility of discontinuing medication urgently and low cost. However, VKAs
have limitations that affect the quality of life of patients and increase morbidity: narrow
therapeutic window (International normalized ratio, INR 2.0-3.0) [3], unpredictable re‐
sponse, systematic control of bleeding, frequent dose adjustments and numerous food and
drug interactions. Also, scenarios such as intercurrent infections and other medical condi‐
tions can also modify the values of the INR [4]. These results indicate that it is important to
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stratify each patient, both the risk of stroke such as bleeding, to individually assess what the
best therapeutic approach in each case.
Due to the complexity of the use of VKAs in routine clinical practice in the last decade has
developed an extensive research activity and has seen the introduction of new oral anticoa‐
gulants (NOACs): The direct thrombin inhibitors (dabigatran) and factor Xa (rivaroxaban
and apixaban) that do not possess the disadvantages of the VKAs. These drugs are charac‐
terized by rapid onset of action, low potential for drug and food interactions and a predicta‐
ble anticoagulant effect that avoids the need to monitor coagulation (Table 1) [5-7].
Comparative features of VKAs and NOACs
Advantage Clinical implications
The rapid onset of action No bridge therapy required
Predictable anticoagulant effect No routine coagulation monitoring required
Diana enzymatic cascade specific clotting Low risk of adverse effects related to its mechanism of action
Low potential for interactions with food No dietary restrictions
Low potential for drug interactions Few drugs restrictions
Table 1. Comparative features of VKAs and NOACs
2. Evaluation of the risk of tromboembolism and bleeding to recommend
anticoagulant therapy in the AF
Currently, there have been scales for assessing the risk of stroke and bleeding in patients
with AF. The risk of stroke is classified into low, moderate and high, depending on the fac‐
tors set out in the CHADS2 scale (Table 2) [8]. A higher score greater risk. Patients at high
risk should receive OACs and low risk, acetylsalicylic acid or nothing (prefer no treatment).
In intermediate-risk patients should consider any of the two treatments.
CHADS2 acronym Score
Congestive Heart failure (CHF) 1
Hypertension 1
Aged ≥ 75 years 1
Diabetes mellitus 1
Stroke or transient ischemic attack (TIA) 2
Maximum score 6
Table 2. Stroke risk stratification with the CHADS2 score
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Given the limitations of CHADS2 scale, a large proportion of patients are classified as inter‐
mediate risk and to the omission of potential risk factors for thromboembolism, there is the
scale CHA2DS2-VASc [9,10]. This new scale is more comprehensive as additional risk factors:
the presence of vascular disease, a younger age range than the CHADS2 and female category
(Table 3). The patients with a grade of 0 are at low risk and should not be treated. The rest
should be considered for oral anticoagulation, establishing the risk of bleeding by HAS-
BLED scale (Table 4) [11]. In patients with a HAS-BLED score ≥3, caution and regular review
are recomended and to correct the potentially reversible risk factors for bleeding. A high
HAS-BLED score per se should not be used to exclude patients from OAC therapy.
CHA2DS2-VASc acronym Score
CHF or LVEF ≤ 40% 1
Hypertension 1
Aged ≥ 75 years 2
Diabetes mellitus 1
Stroke / TIA / Thromboembolism 2
Vacular disease 1
Aged 65-74 years 1
Sex category (Female) 1
Maximum score 9
Table 3. Stroke risk stratification with the CHA2DS2-VASc score
HAS-BLED risk criteria Score
Hypertension 1
Abnormal renal or liver function (1 point
each)
1 or 2
Stroke 1
Bleeding 1
Labile INRs 1
Elderly (age > 65) 1
Drugs or alcohol (1 point each) 1 or 2
Table 4. HAS-BLED risk criteria
If a patient has a rating of less than 2 on the CHADS2 scale, it also assesses the amendment
CHA2DS2-VASc, although this could be applied directly: if the score is zero, who are at low
risk, with none of the risk factors, no antithrombotic treatment is indicated and if the score is
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1, is preferred to administer OACs (VKAs or NOACs) based upon an assessment of the risk
of bleeding complications and patient preferences. If CHA2DS2-VASc score equal to or great‐
er than 2, the treatment is with OACs (VKAs or NOACs) is recommended, unless contrain‐
dicated. When the patients refuse the use of OACs (VKAs or NOACs), antiplatelet therapy
should be considered (combination therapy with acetylsalicylic acid plus clopidogrel).
In patients with CHA2DS2-VASc score of 1, apixaban and both doses of dabigatran (110 mg
twice daily and 150 mg twice daily) had a positive net clinical benefit while, in patients with
CHA2DS2-VASc score ≥2, all three NOACs were superior to warfarin, with a positive net
clinical benefit, irrespective of bleeding risk. The patients with CHA2DS2-VASc equal to 0
have a lower risk of stroke and could be left with acetylsalicylic acid or no treatment, prefer‐
ring the latter option, as it has not shown any benefit in this group without treatment.
When using dabigatran, the dose is 150 mg administered twice daily in patients with low
risk of hemorrhage (HAS-BLED scale of 0 to 2) and 110 mg twice daily in patients with in‐
creased risk hemorrhage (HAS-BLED ≥ 3), elderly patients, concomitant use of interacting
drugs and moderate renal impairment (creatinine clearance (CrCl) 30-49 mL/min) [12].When
using rivaroxaban, the dose is 20 mg daily in the most patients and 15 mg daily en high
bleeding risk (HAS-BLED ≥ 3) and moderate renal impairment (CrCl 30-49 mL/min) [13].
3. Objectives of anticoagulant therapy
Anticoagulant therapy is recommended in patients with AF with risk factors for systemic em‐
bolism. The choice of treatment is based on the absolute risk of stroke, the risk of bleeding and
the risk/benefit ratios for each patient [14]. The recent development of NOACs, with innova‐
tive mechanisms of action of therapeutic targets in the coagulation could change the current
standard anticoagulant drug treatment [15]. The NOACs are orally administered drugs that di‐
rectly inhibit the coagulation steps defined by decreasing or inhibiting thrombin generation of
the final enzyme, thrombin. Thrombin (factor IIa) is the end effector of the coagulation cascade
that catalyzes the formation of fibrin from plasma fibrinogen. Is the most potent physiological
agonist of platelet activation, so it is considered a key therapeutic target in the development of
NOACs. The Factor Xa acts as a point of convergence of the intrinsic and extrinsic pathways of
coagulation and catalyzes the conversion of prothrombin to thrombin [16,17]. A single mole‐
cule of factor Xa can generate more than 1.000 molecule of thrombin, as a consequence the in‐
hibition of factor Xa can block this process by reducing the activation of coagulation and
platelet thrombin mediated. Whether the coagulation cascade is inhibited at the level of throm‐
bin and factor Xa, or even above the sequence, the net result is a decreased activity of thrombin.
The NOACs are characterized by specific inhibition of one of the two key factors in the coag‐
ulation system, factor Xa and thrombin. Dabigatran, MCC977 and AZD0837 acts by directly
inhibiting thrombin thus interfere with the first phase (initial phase) and late (amplification /
propagation phase) the model based on the coagulation system. Rivaroxaban, apixaban,
edoxaban, betrixaban, eribaxaban, LY517717, YM150, TAK-442 and bind to either factor Xa
or factor Xa without bound in the prothrombinase complex thus blocking the conversion of
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prothrombin to thrombin in the early stage (stage start) and end (amplification / propaga‐
tion phase) the model based on the coagulation system.
4. New oral anticoagulants
The search of ideal anticoagulant is one of the most active fields of investigation in lasts
years. The ideal anticoagulant would be one that fulfilled the following characteristics: Oral
administration, effective in the treatment of AF and low bleeding risk, predictable kinetics,
which does not require monitoring of coagulation and platelet count, which is not necessary
to adjust the dose, wide therapeutic range, low drug interaction, cost effective and availabili‐
ty of an effective antidote.
With these premises have been developed more specific inhibitors of coagulation factors:
factor Xa and factor II (thrombin). In Table 5, inspired by Phillips and Ansell collected some
of the most relevant pharmacological characteristics of NOACs (dabigatran, ribaroxaban
and apixaban) compared with VKAs (warfarin and acenocoumarol) [18].
Warfarin Acenocoumarol Dabigatran Rivaroxaban Apixaban
Target VKOR and
factors
II,VII,IX, X
VKOR and factors II,
VII,IX,X
Factor IIa
(Thrombin)
Factor Xa Factor Xa
Time to peak
concentration
72-96 h 1,5-3 h 2-4 h 1-3 h
Vol. of dist. 60-70 l 50 l Reported as low
Half-life 40 h 8-11 h 12-14 h 9-13 h 9-14 h
Metabolism Liver-CYP2C9 Liver- CYP2C9 Conjugation Liver-CYP3A4 and
CYP2J2
Partially through
CYP3A4
Elimination Bile and urine Bile and urine 80% renal,
20% faecal
66% faecal,
33% renal
75% faecal,
25% renal
Administration Once Daily Once Daily Once or
Twice daily
Once daily Twice daily
Monitoring INR INR Not needed Not needed Not needed
Antidote or
potencial therapy
for bleedind
Vitamin K, FFP,
PCC or rFVIIa
Vitamin K, FFP, PCC or
rFVIIa
FFP, PCC or
rFVIIa
FFP, PCC or rFVIIa FFP, PCC or
rFVIIa
Assay PT/INR PT/INR Experimental Experimental Experimental
Drug interactions CYP2C9 PPIs decrease
absorption and
potent P-gp
inhibitors
Potent CYP3A4
inhibitors and P-gp
inhibitors
Potent CYP3A4
inhibitors
VKOR: vitamin K oxidase reductase; CYP: cytochrome P450; PCC: prothrombin complex concentrates; PPIs: proton
pump inhibitors; P-gp: P-glycoprotein; h: hour.
Table 5. Summary of pharmacokinetics and pharmacodynamics of VKAs and NOACs
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The following describes the characteristics of each one of them:
4.1. Dabigatran
It is a potent, selective and reversible thrombin [19]. Has been authorized, among other indi‐
cations, in preventing stroke and systemic embolism in adult patients with non-valvular AF
with one or more risk factors: stroke, transient ischemic attack or previous systemic embo‐
lism, left ventricular ejection fraction <40 %, symptomatic heart failure class ≥ 2 scale New
Cork Heart Association (NYHA), age ≥ 75 years, age ≥ 65 years associated with diabetes mel‐
litus, coronary artery disease or hypertension.
It is administered orally as a prodrug (dabigatran etexilate), which is rapidly transformed by
intestinal bioconversion by esterases to its active form. With a bioavailability of 6.5% for ad‐
equate absorption requires an acidic microenvironment, provided by multiple tartaric acid
microspheres present in the composition of the capsules. It reaches its peak plasma concen‐
tration 2 hours after administration, with slight delays in the presence of food (up to 4
hours) or in the postoperative period (up to 6 hours). Elimination half life is about 12-14
hours. Approximately 20% of the drug is metabolized in the liver and excreted by the biliary
system, independent of cytochrome P450. Most of dabigatran (about 80%) is eliminated re‐
nally as unchanged, so that his administration is contraindicated in patients with severe re‐
nal impairment (CrCl <30 mL/min), requiring administered with caution (setting dose) in
patients with CrCl 30-49 mL/min. No other adjustments are required, except in patients over
75 years, which should decrease the dose. Administration is not recommended if liver en‐
zymes are elevated (transaminases 2 times baseline). Are recommended a baseline measure‐
ment before starting treatment, in patients with severe renal impairment (CrCl <30 mL/min)
or in cases of concomitant quinidine. The main adverse event of dyspepsia is related to the
pharmaceutical formulation. Dabigatran need a daily oral dose and fixed (in two doses), in‐
dependent of age, weight and race, with predictable effects and constant, without significant
interactions with food or other drugs without coagulation controls. The absorption of dabi‐
gatran administration is reduced by approximately 25% with the co-administration of pro‐
ton pump inhibitors. Dabigatran is contraindicated if the patient is treated with systemic
ketoconazole, cyclosporine, itraconazole and tacrolimus, and should be used with caution if
the patient is receiving other potent inhibitors of P-glycoprotein (P-gp): amiodarone, quini‐
dine or verapamil.
4.2. Rivaroxaban
It is a potent and selective inhibitor of factor Xa [20], having peak plasma levels approxi‐
mately 3 hours after oral ingestion. As dabigatran, is indicated for the prevention of stroke
and systemic embolism in adult patients with non-valvular AF, with one or more risk fac‐
tors: congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or attack
transient ischemic. Bioavailability is 80-100% for the dose of 10 mg. Rapidly absorbed and
reaches peak concentrations at 2-4 hours after ingestion. Its plasma half-life is 5 to 9 hours
but increases markedly in people over 75 years from 9 to 13 hours. Not recommended for
use in patients with CrCl <15 mL/min. The intensity of inhibition and, therefore, the genera‐
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tion of thrombin, is dose dependent, meaning that high doses could compromise coagula‐
tion. Has a dual route of elimination: 1/3 of the drug is eliminated via the kidney and 2/3 of
the drug has hepatic metabolism. No interaction was observed with drugs such as acetylsali‐
cylic acid, aluminum hydroxide and magnesium, ranitidine or naproxen. Its bioavailability
increases with inhibitors of CYP3A4 and P-gp, such as ketoconazole and ritonavir, and di‐
minishes with rifampicin. The bioavailability increases only marginally with food.
4.3. Apixaban
It is an oral potent inhibitor reversible and highly selective direct factor Xa [21]. Has greater
affinity for factor Xa attached to clot which is free. Inhibits and delays the generation of
thrombin without significantly affecting platelet aggregation. The oral bioavailability is ap‐
proximately 50%. Rapidly absorbed and reaches peak concentrations at 3-4 hours after in‐
gestion. Food intake does not affect the area under the curve or maximum concentration,
and can be taken with or without food. The binding to plasma proteins is 87%. The half-life
is 12 hours and is metabolized with CYP3A4/5. It is also a substrate binding proteins, P-gp.
Not recommended for use with potent CYP3A4 inhibitors and P-gp and that may increase
exposure to apixaban twice. With the administration of inductors opposite happens. Aproxi‐
mately 25% of the drug is excreted in the urine and more than 50% in the feces. The multiple
elimination pathways suggest that even patients with moderate hepatic or renal impairment
may be suitable for this anticoagulant. No need to monitor renal function.
4.4. Oral anticoagulants under investigation
Currently, there are other investigational drugs: direct thrombin inhibitor (AZD0837 and
MCC977), direct inhibitors of factor Xa (betrixaban, YM150, edoxaban, eribaxaban,
LY517717, TAK-442, otamixaban (parenteral) [22].
5. Monitoring of NOACs
The NOACs not require routine monitoring. However, there are situations where it is advis‐
able to monitor selected patients as those with extreme weights, kidney failure or those who
suffer thrombotic complications being treated with these drugs.
As a result of the occurrence of serious adverse effects, including severe gastrointestinal
bleeding (81 cases) and deaths (260 cases) of bleeding in patients treated with dabigatran
were published safety ratings by the rating agencies worldwide drug advising monitoring
of renal function in patients with moderate renal impairment (30-50 mL/min) receiving dabi‐
gatran and in patients over 75 years. Rivaroxaban is contraindicated if CrCl <15 mL/min,
and should be used with caution if is 15-30 mL/min.
Monitoring is also useful to evaluate the adherence to treatment (the omission of one or
more doses puts the patient at risk of complications at an early stage) or when the patient
needs to undergo an invasive procedure. When subjecting a patient to an invasive proce‐
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dure, it is important to note that the drug half-life (12-14 hours dabigatran, rivaroxaban 9-13
hours and apixaban 9-14 hours). If the invasive procedure has a low bleeding risk, it is suffi‐
cient to suspend the drug 24-36 hours before surgery and if no complications arise, resume
anticoagulant treatment at 36-48 hours [23].
The ideal test for monitoring of direct thrombin inhibitors is the coagulation time of ecarin,
with a linear relationship, and a good slope and discriminate levels of dabigatran in plasma.
The problem is that it is non-standardized and few laboratories possess it.
The studies suggest that dabigatran monitoring will be done with a variant of thrombin time
(TT). TT is very sensitive, with a linear relationship, but with a high slope, so that at low
concentrations of dabigatran, TT extends above the detection limit of the coagulometer. It is
a very good from a qualitative point of view, to assess adherence to treatment, but cannot
quantify levels. The thrombin time will be a diluted thrombin time, marketed as Hemoclot®,
which manages to improve the linear relationship with respect to TT and discriminate be‐
tween low, intermediate and high dabigatran in plasma [24].
Monitoring of rivaroxaban will be done by a method chromogenic anti-factor Xa. This test is
marketed as anti-Xa assay. Is a sensitive and accurate, useful to measure the maximum and
minimum plasma concentrations of rivaroxaban [25,26].
6. Bleeding complications and antidotes
The fear of bleeding complications is one of the most prevalent obstacles in anticoagulant
treatment in AF, especially cerebral hemorrhage.
These drugs have no specific antidotes which is a problem in patients who are at high risk of
bleeding or hemorrhagic. Dabigatran is a dialyzable drug, which can eliminate up to 60% of
the molecule in serum. Other possibilities include the use of activated coal and of neutraliz‐
ing antibodies but are lacking in vivo experience. With respect to rivaroxaban is working in
a variant of factor Xa would compete with the normal to factor Xa when joining rivaroxaban
and thus the effect would be reversed.
In order to reverse the effect of NOACs designed a crossover trial, randomized, double-
blind, placebo-controlled study included 12 healthy male volunteers. Received rivaroxaban
20 mg/12h or dabigatran 15 mg/12h for 2.5 days followed by a single bolus of 50 IU/kg of
prothrombin complex concentrate (PCC) or similar volume of saline. The results concluded
that the PCC completely and immediately reversed the anticoagulant effect of ribaroxaban
but had no influence on the effect of dabigatran at the doses used in this study. These results
should be analyzed with caution due to small sample size (12 patients) and the characteris‐
tics of the population that was part of the study (only male patients and healthy). [27]. An‐
other study found the low doses of non-specific reversal agents (anticoagulant anti-inhibitor
complex with non-activated factors II, IX and X and activated factor VII) appear to be able to
reverse the anticoagulant activity of rivaroxaban or dabigatran. However, clinical evaluation
is needed regarding haemorrhagic situations, and a meticulous risk-benefit evaluation [28].
The absence of normalization of coagulation tests not necessarily correlate with the absence
of anti-haemorrhagic effect, as demonstrated in animal models [24].
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Thus, in a patient treated with dabigatran and rivaroxaban that presents a mild bleeding
complication, it is advisable to delay the next drug administration or discontinuation. If
bleeding is moderate or severe, symptomatic treatment is indicated as mechanical compres‐
sion standard, surgical hemostasis bleeding control procedure, blood products and hemody‐
namic support (packed red cells or fresh frozen plasma). In the case of very severe bleeding
will require charcoal filtration or haemodialysis or administration of an agent for reversing
the specific procoagulant effect, such as prothrombin complex, the prothrombin complex
concentrate or activated recombinant factor VIIa. In this case, experience is limited.
7. Evaluation of scientific evidence, relevance and limitations of the study
It will analyze the scientific evidence, the limitations of design and the clinical relevance of
the results of published clinical trials (RE-LY, ROCKET AF, AVERROES and ARISTOTLE).
In general, these new drugs are at least equally effective and safer than warfarin, with the
advantage of inducing a lesser extent intracerebral hemorrhages (Table 6).
Dabigatran Rivaroxaban Apixaban
(RE-LY) (ROCKET AF) (AVERROES) (ARISTOTLE)
Study design Randomized openlabel
Multicenter,
randomized, double-
blind, double-dummy
Multicenter,
randomized, double-
blind, double-
dummy
Multicenter,
randomized, double-
blind, doble-dummy
Number of patients 18.113 14.264 5.599 18.201
Mean age 71.5 years 73 years 70 years 70 years
Male:female ratio 63.6%: 36.4% 60%:40% 58.5%: 41.5% 64.7%: 35,30%
Follow-up period,
years 2 years 1.9 years 1.1 years 1.8 years
Randomized groups
Dose-ajusted WA vs.
blinded doses of DA
(150 mg BID, 110 mg
BID)
Dose-ajusted WA vs. RI
20 mg OD
AAS 81-324 mg OD
vs. API 5 mg BID
Dose-ajusted WA vs.
API 5 mg BID
Mean CHADS2 score 2.1 3.5 2.1 2.1
Primary endpoint:
stroke and systemic
embolism (in % per
year)
1.71% WA
1.54% DA 110mg
1.11% DA 150mg
2.42% WA
2.12% RI
3.9% AAS
1.7% API
1.60% WA
1.27% API
Major bleeding events
3.57% WA
2.87% DA 110mg
3.32% DA 150mg
3.45% WA
3.6% RI
1.2% AAS
1.4% API
3.09% WA
2.13% API
BID: twice daily; OD: once daily; WA: warfarin; DA: dabigatran; RI: rivaroxaban; API: apixaban; AAS: acetylsalicylic acid
Table 6. Summary of the main clinical trials with NOACs
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7.1. Dabigatran
The RE-LY is  the largest  study of  AF (Randomized Evaluation of  Long term anticoagu‐
lant  therapy)  [29].  The  primary  endpoint  was  to  establish  non-inferiority  of  dabigatran
etexilate  compared with  warfarin  for  a  minimum of  1  year  follow-up to  a  maximum 3
years, median follow-up of 2 years in 18.113 patients with nonvalvular AF (mean age 71
years) with at least one of the following risk factors for stroke: previous stroke or transi‐
ent  ischemic  attack,  left  ventricular  ejection  fraction  <40%,  symptoms  of  heart  failure
class 2 or higher NYHA, age >75 years or 65-74 years associated with diabetes mellitus,
hypertension  or  coronary  artery  disease.  Meanwhile,  we  excluded patients  with:  severe
valvular  disease,  recent  stroke,  (a  condition  that  increases  the  risk  of  bleeding),  CrCl
<30mL/min, active liver disease and pregnancy.
Patients were randomized into three treatment arms: 110 mg dabigatran twice daily, dabiga‐
tran 150 mg twice daily and adjusted dose warfarin (INR 2.0-3.0). In patients randomized to
receive warfarin, the average percentage of time within therapeutic range (INR = 2.0-3.0)
were 64.4%. Dabigatran was administered in a blinded fashion in both treatment arms; the
administration of warfarin was opened. In all branches were allowed concomitant use of
acetylsalicylic acid or other antiplatelet agent. Also allowed the concomitant use of quini‐
dine with dabigatran during the first two years of the study, when it was prohibited by the
possibility of interaction with dabigatran.
The primary endpoint studied was the appearance of stroke or systemic embolic event and
the primary safety outcome was the occurrence of serious bleeding. The criterion for non-
inferiority was established that the upper limit of confidence interval (CI) 97.5% of the rela‐
tive risk of occurrence of stroke or systemic embolism with dabigatran compared to
warfarin was <1.46. The non-inferiority margin was established from the results of a meta-
analysis with VKAs against a control treatment in patients with AF. The value of 1.46 repre‐
sents half of the 95% CI relative risk estimated effect on warfarin control. All analyzes were
by intention to treat (ITT).
The results for the primary endpoint were: onset of stroke or systemic embolism in 182 pa‐
tients in the group treated with dabigatran 110 mg (1.53% per year), in 134 patients with da‐
bigatran 150 mg (1.11% per year) and 199 patients with warfarin (1.69% per year). The two
treatment groups dabigatran meet the criteria for non-inferiority to be the upper limit of
95% relative risk less than 1.46 (1.11 in the first case and 0.82 in the second), but only dabiga‐
tran 150 mg was associated with lower rate of stroke and embolic events than warfarin (RR
= 0.66, 95% CI 0.53 to 0.82), dabigatran 110 mg was similar to warfarin.
Regarding security, in the RE-LY study, the treatment with dabigatran was associated with
an "annual rate" of major bleeding (defined as bleeding associated with a decrease in hemo‐
globin of at least 2g/dL, transfusion of at least 2 units of whole blood or symptomatic bleed‐
ing in a critical organ or area (intraocular, intracranial, intraspinal or intramuscular with
compartment syndrome, retroperitoneal bleeding, bleeding or intra-articular pericardial
bleeding). Severe bleeding was divided in turn into intracranial hemorrhage (intracerebral
or subdural) and extracranial (gastrointestinal or not gastrointestinal). The major bleeds
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were categorized as critical if they met one or more of the following criteria: fatal bleeding,
symptomatic intracranial bleeding, reduced hemoglobin of at least 5g/dL, transfusion of at
least 4 units of whole blood or packed red cells, bleeding associated with hypotension re‐
quiring the use of intravenous inotropic agents, bleeding required surgery) of 2.71% for da‐
bigatran 110 mg, 3.11% for dabigatran 150 mg and 3.36% for warfarin. No significant
difference in major bleeding between dabigatran 150 mg twice daily and warfarin; on the
contrary, dabigatran 110 mg twice daily resulted in less major bleeding, RR 0.80 (95% CI:
0.69 to 0.93) p = 0.003. As for minor bleeding (defined as all non-major bleeding definition,
previously expressed) annual rates were 13.16%, 14.84% and 16.37% for dabigatran 110 mg,
dabigatran 150 mg and warfarin, respectively. In this case, the risk was significantly lower
for dabigatran 110 mg [RR = 0.79 (95% CI: 0.74 to 0.84)] and dabigatran 150 mg [RR = 0.91
(95% CI: 0.85 to 0.97)] with respect to warfarin and was higher for dabigatran 150 mg versus
dabigatran 110 mg [RR = 1.16 (95% CI: 1.08 to 1.24)]. Similarly, the risk of intracranial hemor‐
rhage was significantly lower for dabigatran 110 mg [RR = 0.31 (95% CI: 0.20 to 0.47)] and
for dabigatran 150 mg [RR = 0.40 (95% CI: 0.27 to 0.60)] against warfarin and no significant
differences between the two doses of dabigatran. However, the risk of bleeding severe gas‐
trointestinal was significantly higher in the group treated with dabigatran 150 mg versus
warfarin [RR = 1.50 (95% CI: 1.19 to 1.89)] and versus dabigatran 110 mg [RR = 1.36 (95% CI:
1.09 to 1.70)]. The overall mortality (4%) showed no significant differences (p=0.051) be‐
tween dabigatan 150 mg twice daily and warfarin, although the rate of deaths from vascular
causes was significantly lower in the group treated with dabigatran 150 mg twice daily
(p=0.04).
The results of dabigatran 150 mg dose showed that the benefit is somewhat larger than war‐
farin in CHADS2≥ 2 while the hemorrhagic risk is similar in both groups. In CHADS2 = 0-1
the benefit is also somewhat higher than warfarin while the hemorrhagic risk is somewhat
lower. A dose of 110 mg the benefit and bleeding risk is similar in every category of
CHADS2 except for the category CHADS2 = 0-1 where the risk is somewhat lower.
Dropout  rates  were  higher  with dabigatran:  14.5% with dabigatran 110 mg,  15.5% with
150 mg dabigatran and 10.2% with warfarin the first year and 20.7% with dabigatran 110
mg, 21.2% with dabigatran 150 mg and 16.6% with warfarin the second year. There were
more withdrawals due to serious adverse events with dabigatran (2.7%) than with war‐
farin (1.7%).
The incidence of myocardial infarction was higher with dabigatran 110 mg twice daily
(0.72%, p = 0.07) and dabigatran 150 mg twice daily (0.74%, p = 0.048) than warfarin (0.53%),
having calculated that myocardial infarction could occur for every 500 patients treated with
dabigatran. With the correction of the results of RE-LY study the differentiation in the appa‐
rition of the myocardial infarction no longer statistically significant. However, a meta-analy‐
sis of 7 trials published recently concluded that the use of dabigatran is associated with an
increased risk of myocardial infarction or acute coronary syndrome in a broad spectrum of
patients compared with VKAs, antiplatelet or placebo [30]. Although the absolute risk may
be low, it is necessary to closely monitor patients and the importance of improving pharma‐
covigilance systems [31].
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7.2. Rivaroxaban
The ROCKET AF study (Rivaroxaban Once daily,  oral,  direct  factor  Xa inhibition Com‐
pared with vitamin K for prevention of stroke Antagonism and Embolism Trial in Atrial
fibrillation)  compared  the  clinical  outcomes  of  rivaroxaban  at  doses  of  20  mg/day  (15
mg/day for those with estimated CrCl 30-49 mL/min )  with warfarin dose-adjusted INR
in patients with AF. It is a prospective, randomized, double-blind, parallel group, multi‐
center,  event-based and non-inferiority which involved 14.264 patients.  The patients had
high risgo of stroke (CHADS2  score >2 in 90%) [32, 33]. It was shown that the new anti‐
coagulant was non-inferior to warfarin in the combined primary endpoint, which includ‐
ed stroke and systemic embolism. Embolic events were presented to the central nervous
system or  systemic 1.7% per  year  in  the rivaroxaban group compared with 2.2% in the
warfarin  group,  which  has  met  the  criterion  for  non-inferiority.  However,  ITT  analysis
showed  that  superiority  failed.  The  incidence  rates  of  primary  safety  outcome  (major
bleeding  episodes  and  no  clinically  relevant  non-major  bleeding)  were  similar  in  both
treatment groups but,  with rivaroxaban, there was a significant reduction in fatal bleed‐
ing,  as  well  as  an  increase  in  gastrointestinal  bleeds  and  bleeds  requiring  transfusion.
Premature  discontinuation  of  treatment  was  more  common  with  rivaroxaban  (23.9%)
than with warfarin (22.4%). The duration of follow-up was 12-32 months.
7.3. Apixaban
The AVERROES study is a multicenter, randomized, double-blind and double-dummy
(Apixaban Versus Stroke Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients
Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment) comparing apixa‐
ban 5 mg twice daily (2.5 mg twice daily in patients ≥80 years, weight ≤60 kg or with a se‐
rum creatinine ≥1.5 mg/dL) versus acetylsalicylic acid 81-324 mg daily in 5.599 patients with
AF at high risk of stroke and without indication for treatment with VKAs or by difficulties
in anticoagulation or because the patient refused anticoagulation therapy.
The trial was stopped early, after about a year after intermediate analysis showed a signifi‐
cant reduction of 50% in the risk of stroke. There were 1.6% of cerebral and systemic embolic
events in the apixaban group compared to 3.5% in the acetylsalicylic acid group. The fre‐
quency of bleeding was similar (1.4 versus 1.2% per year); there was no difference between
patients treated with apixaban and acetylsalicylic acid on the incidence of major bleeding,
intracranial hemorrhage, or gastrointestinal bleeding even if appreciate a significant increase
of the total number of bleeding (major and minor). Mortality was lower in the apixaban
group (3.5% per year) than acetylsalicylic acid (4.4% per year), results that corroborate the
greatest benefit of anticoagulant therapy in AF. In patients with AF for whom therapy is in‐
adequate VKAs, apixaban reduces the risk of stroke or systemic embolism without increas‐
ing the risk of major bleeding or intracranial hemorrhage [34].
The ARISTOTLE study is a multicenter, randomized, double-blind and double-dummy
(Apixaban for Reduction in Stroke and Other Events in Atrial Fibrillation thromboembolic)
comparing apixaban 5 mg orally twice daily (2.5 mg twice daily in patients ≥80 years,
weight ≤60 kg or with a serum creatinine ≥1.5 mg/dL) versus adjusted-dose warfarin (INR
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2.0-3.0). The study was designed to demonstrate non-inferiority of apixaban compared to
warfarin. Analysis is performed of non-inferiority trial and after an analysis of superiority.
The primary efficacy endpoint was the composite of stroke and systemic embolism. The pri‐
mary safety outcome was major bleeding. The mean duration of follow-up was 1.8 years.
The study included 18.201 patients with AF at high risk of systemic and cerebral embolism.
Cerebrovascular events were 1.27% per year in the apixaban group versus 1.60% in the war‐
farin group (p <0.001 for non-inferiority and p = 0.01 for superiority), bleeding of 2.13% ver‐
sus 3.09% for year (p <0.001), respectively. Significantly decreased the incidence of any type
of bleeding, major bleeding and intracranial bleeding and not change the frequency of ap‐
pearance of gastrointestinal bleeding. Mortality from all causes was 3.52% versus 3.94%,
demonstrating the superiority of apixaban compared to warfarin in preventing stroke or
central nervous system systemic fewer bleeding complications and lower mortality. Cere‐
brovascular events in patients with CHADS2 ≥3 were 1.9% per year in patients treated with
apixaban compared to 2.8% per year in patients treated with warfarin; CHADS2 = 0-1, 0.7%
per year versus 0.9% per year and CHADS2 = 2, 1.2% per year versus 1.4% per year. In pa‐
tients under 65 years no difference in efficacy between both groups, but in patients over 65
years the difference is 0.9%.
In conclusion, treatment with apixaban compared to warfarin in AF patients with more than
one risk factor reduces the incidence of stroke and systemic embolism by 21% (p = 0.01), re‐
duced major bleeding by 31% (p <0.001) and reduces mortality by 11% (p = 0.047) [35].
7.4. Methodological limitations of studies
Taking into account the results of the studies so far mentioned, there are some differences in
patients enrolled in the RE-LY, the ROCKET AF, the AVERROES and the ARISTOTLE. The
study population ARISTOTLE included subjects both with a CHADS2 score of 1 point and
those of scores. In the RE-LY incorporated population according to the CHADS2 score was
mild-moderate risk (32% of patients with a CHADS2 of 3 to 6 points) and the ROCKET-AF
population included was moderate to severe (87% patients had a CHADS2 risk score (of 3 to
6 points) which makes comparisons difficult between these studies. RE-LY and ARISTOTLE
have similar characteristics on patient demographics (age, gender...) and in the risk of stroke
(average CHADS2 score of 2.1). However, ROCKET AF patients were slightly older (median
age 73 years), were at high risk of stroke (mean CHADS2 score of 3.5), and 55% were a sec‐
ondary prevention population [36]. Exclusion criteria of patients pose leave out AF patients
eligible for treatment with VKAs, as those who have suffered a recent stroke or those with
liver enzyme elevations 2 times the upper limit of normal.
They are non-inferiority studies. The European Medicines Agency (EMEA) recommended in
these studies an ITT and per protocol analysis (PP). In the RE-LY is not a PP (which could
favor dabigatran) and also the non-inferiority margin has questionable clinical relevance.
The superiority analysis showed more effectively to the highest dose of dabigatran. The
ROCKET AF results PP were slightly significant in favor of rivaroxaban while ITT results
demonstrate the non-inferiority of rivaroxaban with warfarin. ARISTOTLE and AVERROES
studies also reflect the non-inferiority of apixaban versus warfarin however, the results were
New Oral Anticoagulants in Atrial Fibrillation
http://dx.doi.org/10.5772/53614
219
better in the Asian population and whether they may be due to different effectiveness of the
drug in this population or whether there was any element related to the study design to jus‐
tify these differences. In addition 35% of patients with warfarin were outside the therapeutic
range, implying poor control within the clinical trial.
In the RE-LY treated with warfarin branch has an open design which favors the appearance
of bias. It would be necessary to make a double-blind design with warfarin (this limits the
internal validity of the test. Both the ROCKET AF as ARISTOTLE was double blind). Dabi‐
gatran is necessary to take it twice a day. This helps to foster low compliance. Only in the
RE-LY study, where patients are monitored closely, the dropout rate was 20.7% with dabi‐
gatran 110 mg and 21.2% with dabigatran 150 mg at two years. The same can happen with
rivaroxaban and apixaban, the absence of regular checks can relax patients. Poor adherence
to treatment would leave the patient exposed because the anticoagulant effect almost com‐
pletely disappear (are drugs with short half-life). Unlike NOACs, with VKAs is necessary to
periodically checks to confirm that are within the therapeutic range, a fact that is achieved in
58-65% of cases. The compliance rate is not always the desired (30% dropout) [37]. A sub‐
group analysis and an FDA report further notes that the benefit of dabigatran is significant
only in those centers where patients have poorer control with warfarin. The results of the
centers with better INR control with warfarin did not show superiority of dabigaran 150 mg
versus warfarin. Improving the monitoring of the INR, the benefits seen for dabigatran com‐
pared to warfarin decreased. The ARISTOTLE study showed no superiority of apixaban in
terms of INR control. The ROCKET AF study the level of INR of warfarin group was very
low which has reduced the conviction to conclusions (55% versus 64.4% of RE-LY and 62%
of ARISTOTLE).
Regarding the dose to be administered there are disputes between the position of the FDA
(Food and Drug Administration) and EMEA. FDA has approved only high doses of dabiga‐
tran (150 mg/12h). Argued that low doses of dabigatran (110 mg/12h), the demonstration of
non-inferior to warfarin, is not as conclusive as with higher doses. In addition to high doses
reduces episodes of stroke but increase bleeding. The lower dose may be indicated in pa‐
tients with increased risk of bleeding. The RE-LY study could not identify a subgroup of pa‐
tients who would benefit from low dose.
Recently has been published a study that try to perform an indirect comparison analysis of
NOACs regarding its efficacy and safety [36]. Despite the limitations of indirect comparison
study (differences in patient population, differences in definition of major bleeding and un‐
blended versus nonblinded/double-blinded comparisons), no profound significant differen‐
ces were found in efficacy between apixaban and dabigatran (both doses) or rivaroxaban.
Dabigatran 150 mg twice daily was superior to rivaroxaban for efficacy (with less stroke and
systemic embolism (by 26%), as well as less hemorrhagic stroke (by 56%, p=0.039 and non‐
disabling stroke (by 40%, p=0.038). There were no significant differences in preventing
stroke and systemic embolism for apixaban versus dabigatran (both doses) or rivaroxaban,
or rivaroxaban versus dabigatran 110 mg twice daily. For the ischemic stroke, there were no
significant differences between the NOACs. Major bleeding was significantly lower with
apixaban versus dabigatran 150 mg twice daily (by 26%) and rivaroxaban (by 34%), but was
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not significantly different from dabigatran 110 mg twice daily. There were no significant dif‐
ferences between apixaban and dabigatran 110 mg twice daily. Apixaban had lower major
or clinically relevant bleeding (by 34%) versus ribaroxaban. When compared with rivaroxa‐
ban, dabigatran 110 mg twice daily was associated with less mayor bleeding (by 23%) and
intracranial bleeding (by 54%). No significant differences myocardial infarction events be‐
tween dabigatan (both doses) and apixaban. However, only a head-to-head direct compari‐
son of the different NOACs would be able to answer the question of efficacy/safety
differences between them in the prevention of stroke in AF.
An advantage of the NACOs proposes absence monitoring. Instead, experts recommend
that in chronic treatment with narrow therapeutic window and potentially serious complica‐
tions (stroke/hemorrhage), lack of control is much more harmful than adequate control. The
regular monitoring to adjust and correct the treatment regimen and distinguish, if complica‐
tions, treatment failure or lack of adherence.
Are emerging post-marketing data on major bleeding and death with dabigatran: Japan (5
deaths and 81 cases of severe reactions), Australia (7 deaths and 24 serious reactions) and
Europe (21 deaths). In the subsequent reanalysis of data from the RE-LY was a higher inci‐
dence of stroke, myocardial infarction and major bleeding compared to those initially re‐
ported, in those over 75 years more extracranial bleeding [38].
No specific antidote proved effective, which hinder the resolution of bleeding emergencies.
In addition, the high cost compared to VKAs is a major limitation. Have been published
some cost-effectiveness data for dabigatran, and dabigatran appears to be cost-effective for
most patients, except in those with very well-controlled INRs [39,40].
8. Current recommendations - Caution
With the entry into force of the NOACs is emerging a new era in anticoagulant therapy.
These drugs are proving to be at least as effective as VKAs without coagulation monitoring,
with a reduction of more serious bleeding (intracranial) and with far fewer potential drug
interactions and food.
But not all advantages. These drugs also have drawbacks and uncertainties about their safe‐
ty, and to their clinical evaluation is needed before definitive recommendations on its use.
Lack of specific antidotes which is a problem in patients who are at high risk of bleeding or
hemorrhage (to negate the effect is included prothrombin complex or factor specifying of
hospitalization and increasing costs associated with treatment), contraindicated in patients
with renal impairment, short half-life (limits its use in patients with poor adherence), with
higher incidence of gastrointestinal bleeding and high cost. In addition, there are no safecy
data long-term selected populations and are generating security alerts.
In the initial euphoria, with the placing on the market NOACs, it is necessary to proceed
with caution. A few years ago, another promising thrombin inhibitor, ximelagatran, which
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showed that it was at least as effective and safe as warfarin for stroke prevention in AF pa‐
tients, had to be withdrawn by its liver toxicity after creating many expectations [41].
All this raises questions: Is it appropriate to change oral anticoagulation with warfarin or
acenocoumarol to a patient controlled? Can these NOACs impact in preventing throm‐
boembolism, especially stroke, in patients with AF? Will we monitor patients? Is it accepta‐
ble despite the cost of not requiring monitoring? How do we assess adherence?
The Canadian Cardiovascular Society (CCS) [41], the European Society of Cardiology (ESC)
[13,42,43], the American College of Cardiology Foundation (ACCF), the American Heart Asso‐
ciation (AHA) and the Heart Rhythm Society (HRS) recently updated their guidelines for the
treatment of patients with AF. The guidelines report that when OAC is recommended, one of
NOACs should be considered rather than adjusted-dose VKAs (INR 2.0-3.0) for most patients
with AF, when studied in clinical trials to date. The NOACs provide better efficacy, safety and
comfort compared to the OAC with VKAs. There is insufficient evidence to recommend one
over another NOACs, although some patient characteristics, drug tolerability and compliance
and the cost may be important factors in the choice of agent. As experience with NOACs is still
limited, strict adherence to the recommended indications approved and aftercare marketing.
The short half-lives of NOACs compared with that do not require routine monitoring of coagu‐
lation, causes adherence is very relevant. Poor adherence increase morbidity, mortality, and in
turn, overall health costs. Poor compliance can be a particular problem in patients with AF who
often has no symptoms. Warfarin has a half life of 40 hours, so that a slight failure of the patient
will have a negligible effect on clotting compared to a drug with short half life.
In this context it is useful to provide a meta-analysis of clinical trials in patients treated with
VKAs. The results showed that patients who achieved a treatment well stabilized, the deter‐
mination home ("self") for the same patient resulted in a significant reduction in mortality
and morbidity from thromboembolism without increasing the risk of serious bleeding in a
selected group of motivated adults [44]. The results of a subsequent meta-analysis showed a
reduced risk of thromboembolic disease, but no major bleeding or mortality [45].
The NOACs will not replace the classical therapy of oral anticoagulant therapy automatical‐
ly. As a general rule, you should not change the anti-clotting drug to patients who are cur‐
rently well controlled with acenocoumarol or warfarin and have an INR within the
therapeutic range. The NOACs be reserved for those who have not attained regular values
(between 2.0 and 3.0) the INR by more than 60% of the determinations despite good adher‐
ence to the prescription by the patient (for drug interactions that hinder the anticoagulation
control, special dietary or digestive disorders that affect the pharmacokinetics of VKAs.
Should not switch to dabigatran in patients with inadequate control of INR and nonadher‐
ence) [46], for those with mobility problems or difficulties traveling to determine the INR
and for which have allergies or intolerance to the adverse effects of OACs. An anticoagulant
is, by definition, a drug of high risk. And a patient with AF generally well. The fact that new
drugs is involved uncertainty about their safety in the short and long term. You have to de‐
fine more precisely the role of new drugs, considered as therapeutic innovations, and they
are accompanied by a careful evaluation of their efficacy and toxicity in actual practice.
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The experience of use and new studies will determine the profile of patient who may benefit
most from these new therapies. Be taken into account: stage of disease, the left atrial size,
presence and severity of underlying disease, therapeutic approaches and patient preferen‐
ces. It also assessed the patients' age, presence of comorbidities and polypharmacy. Ad‐
vanced age increases the impact of AF on the embolic risk. The elderly population is
particularly vulnerable to stroke in AF. In addition, stroke patients with AF have increased
mortality and the consequences are devastating.
9. Conclusions
Clinical trials available to date show that NOACs are at least as effective and safe as VKAs.
However, although the evidence is a useful tool, it should await the development of major
clinical studies in different populations to see the real benefit of these drugs. The main prob‐
lems are lacking proven methods of monitoring, so that in certain patients (elderly, low
weight, renal or liver impairment...) fixed dose may not be therapeutic. There are no conclu‐
sive data on its long-term safety and are already generating security alerts in different coun‐
tries. No studies support the use of an antidote in case of overdose with bleeding. There is
no justification to replace the current oral anticoagulant treatment by the NACOs in patients
that conventional treatment is well tolerated and its controls are stable. Its high cost limits
the use of these drugs. Independent trials are needed to precisely define the role of new
drugs in patients with non-valvular AF.
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